News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
287,231 Results
Type
Article (15296)
Company Profile (300)
Press Release (271627)
Multimedia
Podcasts (78)
Webinars (12)
Section
Business (80953)
Career Advice (240)
Deals (13589)
Drug Delivery (40)
Drug Development (51669)
Employer Resources (33)
FDA (6014)
Job Trends (5324)
News (147693)
Policy (10358)
Tag
2027 Biotech Bay Standard (1)
2027 Genetown Elite (1)
2027 Genetown Standard (1)
2027 Pharm Country Standard (2)
Academia (948)
Accelerated approval (20)
Adcomms (15)
Allergies (83)
Alliances (22109)
ALS (127)
Alzheimer's disease (1038)
Antibody-drug conjugate (ADC) (261)
Approvals (6221)
Artificial intelligence (264)
Autoimmune disease (113)
Automation (10)
Bankruptcy (107)
Best Places to Work (4710)
BIOSECURE Act (6)
Biosimilars (104)
Biotechnology (231)
Bladder cancer (103)
Brain cancer (48)
Breast cancer (384)
Cancer (3251)
Cardiovascular disease (252)
Career advice (206)
Career pathing (9)
CAR-T (218)
CDC (6)
Cell therapy (565)
Cervical cancer (19)
Clinical research (44572)
Collaboration (1165)
Company closure (2)
Compensation (593)
Complete response letters (39)
COVID-19 (1149)
CRISPR (86)
C-suite (553)
Cystic fibrosis (113)
Data (4442)
Denatured (15)
Depression (92)
Diabetes (263)
Diagnostics (1465)
Digital health (10)
Diversity (5)
Diversity, equity & inclusion (10)
Drug discovery (189)
Drug pricing (49)
Drug shortages (5)
Duchenne muscular dystrophy (214)
Earnings (32242)
Editorial (25)
Employer branding (5)
Employer resources (31)
Events (52359)
Executive appointments (622)
FDA (7817)
Fibrodysplasia Ossificans Progressiva (6)
Friedreich's ataxia (9)
Frontotemporal dementia (22)
Funding (994)
Gene editing (183)
Generative AI (21)
Gene therapy (491)
GLP-1 (527)
Government (1185)
Grass and pollen (4)
Guidances (172)
Healthcare (6755)
HIV (20)
Huntington's disease (44)
IgA nephropathy (81)
Immunology and inflammation (194)
Immuno-oncology (40)
Indications (68)
Infectious disease (1257)
Inflammatory bowel disease (156)
Inflation Reduction Act (10)
Influenza (38)
Intellectual property (170)
Interviews (35)
IPO (7478)
IRA (13)
Job creations (889)
Job search strategy (176)
JPM (41)
Kidney cancer (10)
Labor market (23)
Layoffs (249)
Leadership (13)
Legal (1451)
Liver cancer (44)
Longevity (11)
Lung cancer (438)
Lymphoma (257)
Machine learning (24)
Management (7)
Manufacturing (375)
MASH (132)
Medical device (2767)
Medtech (2776)
Mergers & acquisitions (6744)
Metabolic disorders (757)
Multiple sclerosis (104)
NASH (13)
Neurodegenerative disease (232)
Neuropsychiatric disorders (70)
Neuroscience (1969)
Neurotech (1)
NextGen: Class of 2026 (2080)
Non-profit (903)
Now hiring (30)
Obesity (352)
Opinion (130)
Ovarian cancer (135)
Pain (108)
Pancreatic cancer (162)
Parkinson's disease (233)
Partnered (12)
Patents (307)
Patient recruitment (331)
Peanut (43)
People (26788)
Pharmaceutical (44)
Pharmacy benefit managers (6)
Phase 1 (15668)
Phase 2 (20664)
Phase 3 (13201)
Pipeline (3303)
Policy (92)
Postmarket research (899)
Preclinical (6619)
Press Release (30)
Prostate cancer (150)
Psychedelics (50)
Radiopharmaceuticals (239)
Rare diseases (655)
Real estate (1476)
Recruiting (13)
Regulatory (10170)
Reports (19)
Research institute (997)
Resumes & cover letters (32)
Rett syndrome (24)
RNA editing (21)
RSV (19)
Schizophrenia (125)
Series A (184)
Series B (135)
Service/supplier (1)
Sickle cell disease (77)
Special edition (18)
Spinal muscular atrophy (121)
Sponsored (15)
Startups (2023)
State (1)
Stomach cancer (6)
Supply chain (33)
Tariffs (18)
The Weekly (62)
Vaccines (354)
Venture capital (69)
Weight loss (189)
Women's health (26)
Worklife (4)
Date
Last 7 days (352)
Last 30 days (1226)
Last 365 days (18171)
2026 (1679)
2025 (18478)
2024 (20887)
2023 (22729)
2022 (27197)
2021 (28176)
2020 (23813)
2019 (16624)
2018 (12118)
2017 (14045)
2016 (12168)
2015 (14690)
2014 (10633)
2013 (7658)
2012 (7765)
2011 (7864)
2010 (7586)
Location
Africa (170)
Alabama (65)
Alaska (2)
Arizona (74)
Arkansas (6)
Asia (18853)
Australia (3156)
California (7164)
Canada (1867)
China (793)
Colorado (248)
Connecticut (258)
Delaware (239)
Europe (39995)
Florida (919)
Georgia (216)
Hawaii (2)
Idaho (18)
Illinois (401)
India (35)
Indiana (175)
Iowa (11)
Japan (266)
Kansas (80)
Kentucky (9)
Louisiana (8)
Maine (11)
Maryland (750)
Massachusetts (5625)
Michigan (110)
Minnesota (254)
Mississippi (3)
Missouri (33)
Montana (16)
Nebraska (5)
Nevada (38)
New Hampshire (21)
New Jersey (1747)
New Mexico (13)
New York (1782)
North Carolina (833)
North Dakota (6)
Northern California (3514)
Ohio (181)
Oklahoma (11)
Oregon (24)
Pennsylvania (1301)
Puerto Rico (10)
Rhode Island (25)
South America (238)
South Carolina (9)
Southern California (2850)
Tennessee (42)
Texas (917)
United States (23729)
Utah (99)
Virginia (140)
Washington D.C. (38)
Washington State (599)
West Virginia (1)
Wisconsin (46)
287,231 Results for "an2 therapeutics inc.rss".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
AN2 Therapeutics to Participate in Fireside Chat at Evercore HealthCONx Conference
November 6, 2025
·
1 min read
Press Releases
AN2 Therapeutics Announces FDA Clearance to Proceed with 90-Patient Investigator-Initiated Trial (IIT) of Epetraborole in Patients with M. abscessus Lung Disease
January 12, 2026
·
5 min read
Press Releases
AN2 Therapeutics Reports Third Quarter 2025 Financial Results and Recent Business and Scientific Highlights
November 12, 2025
·
12 min read
Press Releases
AN2 Therapeutics Commences First-in-Human Clinical Trial of Oral AN2-502998 for Chagas Disease
August 12, 2025
·
5 min read
Press Releases
AN2 Therapeutics Announces Research Collaboration With GSK to Advance Boron-Based LeuRS-Inhibitors Targeting Tuberculosis (TB)
November 11, 2025
·
3 min read
Press Releases
AirNexis Therapeutics Launches with $200M Series A to Advance Phase 2 Dual PDE3/4 Inhibitor AN01 for Chronic Obstructive Pulmonary Disease (COPD)
January 9, 2026
·
2 min read
Press Releases
AN2 Therapeutics Reports Second Quarter 2025 Financial Results and Recent Business and Scientific Highlights
August 12, 2025
·
12 min read
Press Releases
AN2 Therapeutics to Participate in Citizens JMP Life Sciences Conference
April 30, 2025
·
1 min read
Press Releases
AN2 Therapeutics and DNDi Collaborate on Clinical Development of Promising New Oral Compound to Treat Chronic Chagas Disease
July 23, 2025
·
8 min read
Layoffs
AN2 Therapeutics Laying Off Half Its Workforce
AN2 is discontinuing a study that evaluated epetraborole for treatment-refractory MAC lung disease and plans to shift focus to its boron chemistry platform.
August 9, 2024
·
1 min read
·
Angela Gabriel
1 of 28,724
Next
